AstraZeneca Trial Miss Leaves Citi Bullish on Broader Pipeline
Citi says AstraZeneca’s breast cancer setback is manageable as a narrower Etcamah launch and wider pipeline support its valuation.

Every Stocks story we have published, newest first.
78 stories in the last 24 hours
Updated 1:35 PM (Times shown in New York time (ET))
Page 25 of 25 · 584 stories
Citi says AstraZeneca’s breast cancer setback is manageable as a narrower Etcamah launch and wider pipeline support its valuation.

Micron’s 5.2% drop reflects a broader retreat from AI-linked semiconductors ahead of its September 30 earnings report.

The infrastructure provider’s huge backlog is colliding with new questions about AI’s pace, economics and capital intensity.

Cathie Wood’s latest trades favor Meta’s consumer AI distribution while trimming Alphabet exposure amid a shifting search landscape.

Oracle's executive chairman canceled a 50-million-share trading plan just a day after disclosing it, as the stock sits down 22% for the year.

A federal appeals court found sports-outcome contracts on prediction platforms are gambling, not swaps, lifting the legacy sportsbooks that lost ground to Kalshi.

Jim Cramer's lightning-round endorsement of Akamai spotlights a bet that cybersecurity and Nvidia-linked cloud contracts can outrun its fading content-delivery roots.

e.l.f. Beauty's rhode expands to 22 countries at once while Chipotle pushes into Mexico and the Middle East, both betting existing fan bases can offset domestic softness.
